Submissions from 2024
A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE), Manmeet Ahluwalia, Yazmin Odia, and Ahmad Ozair
A Phase I/II Study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metasteses, Rupesh Kotecha, Yazmin Odia, Zhijian Chen, Amy K. Starosciak, Alonso La Rosa de los Rios, Susana Herrera, Miguel Ramirez Menendez, Cristina Pow-Sang, Suyen Ramos, Jennifer Perez, Manmeet Ahluwalia, and Minesh Mehta
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL), Manmeet Ahluwalia and Ahmad Ozair
Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer, Andrew Barsky, Jerry George, Andrew Wroe, Kathryn Mittauer, Adeel Kaiser, Roberto Herrera, Jen Yu, Alonso Gutierrez, Diane Alvarez, James McCulloch, Michael Kasper, Minesh Mehta, and Michael Chuong
Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline, Alessandro Villa
Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application, Manmeet Ahluwalia
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies, Garje Rohan and Bruno Bastos
Quality assurance of an established online adaptive radiotherapy program: patch and software upgrade, Michael Chuong, Rupesh Kotecha, Yonatan Weiss, Minesh Mehta, Alonso Gutierrez, and Kathryn Mittauer
Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice, Minesh Mehta
Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease, Haley Appel, Muni Rubens, Mukesh Roy, Rupesh Kotecha, Matthew Hall, Minesh Mehta, Zhijian Chen, Manmeet Ahluwalia, and Yazmin Odia
Outpatient administration of CAR T-cell therapy: a focused review with recommendations for implementation in community based centers, Ariel Perez, Tiba Al Sagheer, George Nahas, and Yuliya Linhares
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon, Yazmin Odia
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma, Yazmin Odia, Doured Daghistani, and Matthew Hall
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort, Yazmin Odia and Matthew Hall
Diagnostic terminology for benign/low-risk tumors on renal cytology, Andrew Renshaw
In Reply to Cellini and Fiore, Michael Chuong
Intersection of Race and Gender in the Cardiothoracic Workforce: Study of Representation and Salary, Ian Bostock
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta